Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
133 hedge funds and large institutions have $485M invested in Cymabay Therapeutics in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 29 reducing their positions, and 32 closing their positions.
511% more call options, than puts
Call options by funds: $7.81M | Put options by funds: $1.28M
86% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 29
6% less funds holding
Funds holding: 142 → 133 (-9)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
47% less capital invested
Capital invested by funds: $907M → $485M (-$422M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$22.4M |
| 3 |
Millennium Management
New York
|
+$14.5M |
| 4 |
Citigroup
New York
|
+$6.37M |
| 5 |
BlackRock
New York
|
+$5.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$24.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.5M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Jane Street
New York
| – | -$433K | -32,623 | Closed |
|
152
Two Sigma Advisers
New York
| – | -$286K | -21,500 | Closed |
|
|
AIM
153
Assured Investment Management
New York
| – | -$209K | -15,717 | Closed |
|
154
Stifel Financial
St. Louis,
Missouri
| – | -$179K | -13,500 | Closed |
|
155
HighTower Advisors
Chicago,
Illinois
| – | -$159K | -12,020 | Closed |
|
|
TI
156
Trexquant Investment
Stamford,
Connecticut
| – | -$157K | -11,794 | Closed |
|
157
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$136K | -10,260 | Closed |
|
|
KPW
158
Kore Private Wealth
New York
| – | -$7K | -500 | Closed |
|
159
US Bancorp
Minneapolis,
Minnesota
| – | -$7K | -500 | Closed |
|
|
QT
160
Quantamental Technologies
White Plains,
New York
| – | -$4K | -300 | Closed |
|
|
CHP
161
Cable Hill Partners
Portland,
Oregon
| – | -$3K | -193 | Closed |
|
162
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | -80 | Closed |
|
|
WEC
163
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$2K | -80 | Closed |
|
|
HR
164
Howe & Rusling
Rochester,
New York
| – | -$1K | -50 | Closed |
|
CBAY Hedge Fund Activity: Q2 2019 in Review
133 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2019, worth a combined $485M — down 47% from $907M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CBAY and 25 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 54 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $44.1M. The largest seller was OrbiMed, exiting entirely with an estimated $24.9M sold.
- 133 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2019, down from 142 in Q1 2019.
- Funds reported $485M of Cymabay Therapeutics stock for Q2 2019, down 47% quarter-over-quarter.
- 25 funds opened new Cymabay Therapeutics positions in Q2 2019 and 32 closed out, a net change of -7 holders.
- The largest Cymabay Therapeutics buyer in Q2 2019 was Point72 Asset Management, an estimated $44.1M added.
- The largest Cymabay Therapeutics seller in Q2 2019 was OrbiMed, an estimated $24.9M sold.
Based on aggregated 13F filings for Q2 2019.